Publication

Improved overall survival in melanoma with combined dabrafenib and trametinib.

Robert, C
; 
Karaszewska, B
; 
Schachter, J
; 
Rutkowski, P
; 
Mackiewicz, A
; 
Stroiakovski, D
; 
Lichinitser, M
; 
Dummer, R
; 
Grange, F
; 
Mortier, L
... show 10 more
Citations
Altmetric:
Abstract
The BRAF inhibitors vemurafenib and dabrafenib have shown efficacy as monotherapies in patients with previously untreated metastatic melanoma with BRAF V600E or V600K mutations. Combining dabrafenib and the MEK inhibitor trametinib, as compared with dabrafenib alone, enhanced antitumor activity in this population of patients.
Authors
Robert, C
Karaszewska, B
Schachter, J
Rutkowski, P
Mackiewicz, A
Stroiakovski, D
Lichinitser, M
Dummer, R
Grange, F
Mortier, L
Chiarion-Sileni, V
Drucis, K
Krajsova, I
Hauschild, A
Lorigan, Paul C
Wolter, P
Long, G
Flaherty, K
Nathan, P
Ribas, A
Martin, A
Sun, P
Crist, W
Legos, J
Rubin, S
Little, S
Schadendorf, D
Affiliation
Gustave Roussy and INSERM Unité 981, Villejuif-Paris Sud
Description
Date
2015-01-01
Publisher
Collections
All Christie Publications
Show all metadata
Keywords
Type
Article
Citation
Improved overall survival in melanoma with combined dabrafenib and trametinib. 2015, 372 (1):30-9 N Engl J Med
Journal Title
Journal ISSN
Volume Title
URI
http://hdl.handle.net/10541/345293
Embedded videos